Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Compass TherapeuticsCMPX +2.67%26 Price-to-Tangible-Book is 2.51 as of Aug. 18, 2026, which is 6% above its 10-year median of 2.36. GuruFocus rates CMPX with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,133 Biotechnology companies, Compass Therapeutics ranks better than 60.02% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Compass Therapeutics Price-to-Tangible-Book Related Terms
Compass Therapeutics Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Compass Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMPX vs CCCC, AVIR, STRO: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Compass Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Therapeutics Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Compass Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Compass Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Compass Therapeutics (CMPX) has a Price-to-Tangible-Book of 2.51 as of Aug. 18, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Compass Therapeutics and its competitors. This is near median its historical median of 2.36. Over the past decade, Compass Therapeutics' Price-to-Tangible-Book has ranged from 0.94 to 10.54. According to the industry distribution chart, Compass Therapeutics ranks #453 out of 1133 companies in the Biotechnology industry, placing it in the top 40%.
Is Compass Therapeutics' Price-to-Tangible-Book too high?
Compass Therapeutics' current Price-to-Tangible-Book of 2.51 is near median its 10-year median of 2.36. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 10.54. The Biotechnology industry median Price-to-Tangible-Book is 3.20. Compass Therapeutics' value of 2.51 is 21.6% below this industry median. Based on the distribution chart, Compass Therapeutics ranks #453 out of 1133 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Compass Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' Price-to-Tangible-Book compare to CCCC and AVIR?
According to the Biotechnology industry distribution chart, Compass Therapeutics ranks #453 out of 1133 companies for Price-to-Tangible-Book. This puts Compass Therapeutics in the upper half of its industry. The industry median Price-to-Tangible-Book is 3.20. Compass Therapeutics' value of 2.51 is 21.6% below this benchmark. Historically, Compass Therapeutics' own Price-to-Tangible-Book has ranged from 0.94 to 10.54 over the past decade. While the company's 10-year median is 2.36 vs. the industry median of 3.20, Compass Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.20, based on 1,133 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compass Therapeutics's current Price-to-Tangible-Book of 2.51 is 21.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Compass Therapeutics and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compass Therapeutics's current Price-to-Tangible-Book is 2.51, which is near median its own 10-year median of 2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current Price-to-Tangible-Book of 2.51. The current Price-to-Tangible-Book is 2.51, which is near median its 10-year median of 2.36 and 21.6% below the Biotechnology industry median of 3.20. Compass Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current Price-to-Tangible-Book is 2.51 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
26GF Score
Get the complete analysis for CMPX
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMPX has been successfully added to your 
